Status | Study |
Not yet recruiting |
Study Name: A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma Condition: Soft Tissue Sarcoma Bone Sarcoma Chondrosarcoma Date: 2016-11-29 Interventions: Drug: Ipilimumab Ipilimumab 1 |
Recruiting |
Study Name: Observational Study on Endometrial Stromal Tumors Condition: Endometrial Stromal Tumors Date: 2016-07-08 Interventions: Other: Treatment for EST Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to |
Completed |
Study Name: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 Condition: Adrenocortical Adenoma Endometrial Stromal Sarcomas Date: 2014-05-15 Interventions: Procedure: MRI, CT or ultrasound was permitted if MRI was contraindicated |
Completed |
Study Name: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Condition: Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Date: 2010-09-25 Interventions: Biological: Trebananib Given IV Other Names: |
Completed |
Study Name: Collecting Tumor Samples From Patients With Gynecological Tumors Condition: Borderline Ovarian Clear Cell Tumor Borderline Ovarian Serous Tumor Date: 2009-05-09 Interventions: Other: Laboratory Biomarker Analysis Correlative studies |
Completed |
Study Name: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Condition: Adult Fibrosarcoma Adult Leiomyosarcoma Adult Liposarcoma Date: 2008-04-15 Interventions: Drug: saracatinib Given orally Other Name: AZD0530 |
Completed |
Study Name: Mifepristone for Patients With Endometrial Cancer and LGESS Condition: Endometrial Cancer Date: 2007-07-19 Interventions: Drug: Mifepristone 200 mg by mouth (PO) Daily x 4 Weeks |